Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction:
Design and rationale for the MULTI-STRATEGY trial
To access this article, please choose from the options below
The conduct of this study was partially supported by Merck Company (Whitehouse Station, NJ).
PII: S0002-8703(07)00245-1
doi:10.1016/j.ahj.2007.03.023
© 2007 Mosby, Inc. All rights reserved.
